Drugs in Inflammatory Bowel Diseases

Dear Colleagues,

Inflammatory bowel diseases (IBDs) make up a group of idiopathic, chronic, relapsing, and inflammatory conditions, which include ulcerative colitis and Crohn’s disease. These disorders are characterized by intestinal symptoms associated with chronic inflammation of the intestinal mucosa, such as gut dysmotility and visceral pain. A common denominator observed in IBD patients is deregulated intestinal mucosa functions, as well as the exuberant activity of immune cell populations. Indeed, it is widely recognized that in genetically susceptible hosts, pathologic immune responses with an imbalanced interaction with luminal microbes compromise the intestinal epithelial barrier, triggering the development of chronic intestinal inflammation.

Currently, the pharmacological management of IBD patients is far from satisfactory. Indeed, the insufficient efficacy and safety of traditional drugs (i.e., corticosteroids, immunosuppressants, and salicylates), as well as recent biotechnological drugs (including anti-TNF and other biologic treatments), have spurred the interest of the scientific community who have sought to identify novel molecular targets for the management of the immune inflammatory components and visceral hypersensitivity associated with IBDs.

On these bases, this Special Issue, entitled “Drugs in Inflammatory Bowel Diseases”, invites researchers to contribute with original research articles, review articles, and short communications related to all aspects of developing new therapeutic agents or therapeutic strategies for the management of IBDs.

Dr. Vanessa D'Antongiovanni
Dr. Carolina Pellegrini
Guest Editors

Manuscript Submission Information

Manuscripts should be submitted online at www.mdpi.com by registering and logging in to this website. Once you are registered, click here to go to the submission form. Manuscripts can be submitted until the deadline. All submissions that pass pre-check are peer-reviewed. Accepted papers will be published continuously in the journal (as soon as accepted) and will be listed together on the special issue website. Research articles, review articles as well as short communications are invited. For planned papers, a title and short abstract (about 250 words) can be sent to the Editorial Office for assessment.

Submitted manuscripts should not have been published previously, nor be under consideration for publication elsewhere (except conference proceedings papers). All manuscripts are thoroughly refereed through a single-blind peer-review process. A guide for authors and other relevant information for submission of manuscripts is available on the Instructions for Authors page. International Journal of Molecular Sciences is an international peer-reviewed open access semimonthly journal published by MDPI.

Please visit the Instructions for Authors page before submitting a manuscript. There is an Article Processing Charge (APC) for publication in this open access journal. For details about the APC please see here. Submitted papers should be well formatted and use good English. Authors may use MDPI's English editing service prior to publication or during author revisions.